Among patients who were DLL3-positive (≥25% of tumor cells positive for DLL3) (287 patients) and patients with high DLL3 positivity (≥75% of tumor cells positive for DLL3) (238 patients), the best ORR was 20.6% and 21.8%, respectively. The gene discussed is DLL3; the disease is neoplasm.